Should additional imaging or ctDNA surveillance be considered for triple negative breast cancer patients who did not attain pCR after neoadjuvant chemotherapy and immunotherapy?
Should additional imaging or ctDNA surveillance be considered for triple negative breast cancer patients who did not attain pCR after neoadjuvant chemotherapy and immunotherapy? | Mednet
